Tom joined Pappas Capital in 2018 and has more than 30 years of executive management experience in the life science and medical device industries. He operates out of Boston and focuses primarily on company formation. Tom currently serves as the Executive Chairman of the Board for Aer Therapeutics, Inc., a Pappas Ventures VI portfolio company. He also serves as Treasurer and a member of the Executive Committee of the Board of Directors for the Biotechnology Innovation Organization (BIO), where he is active in the areas of advocacy, regulatory policy, capital formation, bioethics and intellectual property policy.

In 2019, Tom founded Allievex Corp., a Pappas Ventures V portfolio company, and served as its President and CEO, as well as a director, until 2024. Prior to Allievex, He was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Pappas Ventures III founded company, which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in 2017 in an all-cash transaction worth nearly $1 billion. Prior to CoLucid, Tom was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc.; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.

Tom is also a Member of the Department of Veteran’s Affairs Research Advisory Committee on Gulf War Veterans’ Illnesses (RACGWVI). Previously, he served as a director for LifeSci Acquisition Corporation II (NASDAQ: LSAQ), as a board observer for Solu Therapeutics, Inc. and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT), and as a business advisor to the Progeria Research Foundation.

From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War.

Education:

United States Military Academy at West Point (BS in Engineering)